Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical instruments maker Harvard Bioscience (HBIO +2.16%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Harvard Bioscience and see what CAPS investors are saying about the stock right now.
Harvard Bioscience facts
|
Headquarters (founded) |
Holliston, Mass. (1901) |
|
Market Cap |
$132.3 million |
|
Industry |
Life sciences tools and services |
|
Trailing-12-Month Revenue |
$112.0 million |
|
Management |
Chairman/CEO Chane Graziano |
|
Return on Equity (average, past 3 years) |
11.1% |
|
Cash/Debt |
$20.3 million / $15.3 million |
|
Competitors |
Becton Dickinson |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 166 members who have rated Harvard Bioscience believe the stock will outperform the S&P 500 going forward.
This past weekend, one of those bulls, All-Star TMFDeej, helped bring the special opportunity to our community's attention:
Harvard Bioscience is in the process of spinning off its money-losing HART division, leaving behind a manufacturer of scientific instruments trading for only three times earnings, yet growing at 15% to 20% per year. See Jim Royal's great article on the situation for more information.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
